Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Clinical Practice
  3. Oncology and Hematology

TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Comments
  • Overview

    SunRISe-5: A phase 3, randomized, open-label study of TAR-200 compared with intravesical chemotherapy after Bacillus Calmette-Guérin in recurrent high-risk non–muscle-invasive bladder cancer.

    Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.

Recommended
Details
Comments
  • Overview

    SunRISe-5: A phase 3, randomized, open-label study of TAR-200 compared with intravesical chemotherapy after Bacillus Calmette-Guérin in recurrent high-risk non–muscle-invasive bladder cancer.

    Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.

Schedule4 Oct 2024